List of Vancomycin drug patents

Vancomycin is owned by Xellia Pharms Aps.

Vancomycin contains Vancomycin.

Vancomycin has a total of 4 drug patents out of which 0 drug patents have expired.

Vancomycin was authorised for market use on 26 August, 2021.

Vancomycin is available in solution;intravenous, oral dosage forms.

Vancomycin can be used as method of treating bacterial infections.

The generics of Vancomycin are possible to be released after 06 November, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188697 XELLIA PHARMS APS Glycopeptide compositions
Nov, 2035

(12 years from now)

US10039804 XELLIA PHARMS APS Glycopeptide compositions
Nov, 2035

(12 years from now)

US11000567 XELLIA PHARMS APS Glycopeptide compositions
Nov, 2035

(12 years from now)

US10849956 XELLIA PHARMS APS Glycopeptide compositions
Nov, 2035

(12 years from now)

Drugs and Companies using VANCOMYCIN ingredient

Market Authorisation Date: 26 August, 2021

Treatment: Method of treating bacterial infections

Dosage: SOLUTION;INTRAVENOUS, ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic